Mediwound (MDWD) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
- Market cap
- $168M
- As of Nov 13, 2026
- P/E
- -7.00x
- Latest fiscal year
- P/B
- 3.82x
- Latest reported equity
- P/S
- 9.88x
- Latest fiscal year
- ROE
- -54.5%
- Latest fiscal year
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $168M
- As of Nov 13, 2026
- P/E
- -7.00x
- Latest fiscal year
- P/B
- 3.82x
- Latest reported equity
- P/S
- 9.88x
- Latest fiscal year
- ROE
- -54.5%
- Latest fiscal year
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Latest fiscal year
Latest fiscal-year financials · Computed in-house by ChickenStock
P/E
-7.00x
Net loss — not comparable
P/B
3.82x
P/S
9.88x
Earnings and dividend metrics▾
Earnings
EPS
-$1.85
Earnings per share
BPS
$3.38
Book value per share
ROE
-54.5%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $1.85 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $3.38 of net assets.
- ROE — shareholder equity shrank by 54.5% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsApr–Jun 2025(FY2025 Q2)
No later quarterly filing was found for this company, so this shows the most recent quarter on record.
Revenue increased 20.0% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $5M+20.0%
—
FY22 Q2
$5M
Apr–Jun '24
$6M
Apr–Jun '25
Blank bars mark quarters with no figure found in the filings.
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Apr–Jun 2025 are from the 6-K submitted to SEC EDGAR on Aug 14, 2025.
- Earnings per share decreased 1,330.0% from the same quarter a year earlier.
- Revenue increased 20.0% from the same quarter a year earlier.
- Operating income decreased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income decreased 1,400.0% from the same quarter a year earlier.
Filed Aug 14, 2025 · 6-K · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Gonen OferChief Executive Officer · Nov 11, 2026Option exercise (expiring)8,168 shares · $110KAvg. price $13.47566,019 shares held after
- SHAMIR NACHUMDirector · Nov 10, 2026Option exercise (expiring)16,336 shares · $220KAvg. price $13.47572,151 shares held after
- Fox David MortonDirector · Nov 10, 2026Option exercise (expiring)6,534 shares · $88KAvg. price $13.47528,817 shares held after
- Rubinstein SamuelDirector · Sep 1, 2026Open-market sale525 shares · $7KAvg. price $12.720 shares held after
- Rubinstein SamuelDirector · Sep 1, 2026Open-market purchase525 shares · $7KAvg. price $12.62525 shares held after
- Hess ShmuelCOO & Chief Commercial Officer · Aug 27, 2026Open-market sale3,958 shares · $51KAvg. price $12.9230 shares held after
Show 2 price lots
- 1,979 shares × $13.126$26K
- 1,979 shares × $12.72$25K
- Hess ShmuelCOO & Chief Commercial Officer · Aug 26, 2026Open-market sale1,865 shares · $24KAvg. price $130 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Mediwound (MDWD) stock information
NASDAQ
Mediwound (MDWD) is listed on NASDAQ. Its market capitalization is about $168M. On trailing-twelve-month earnings the P/E ratio is -7, and the P/B ratio is 3.82. Return on equity is -54.5%. These figures are computed in-house from official filings and are reference information only.
Mediwound — frequently asked questions
- What is the P/E ratio of Mediwound (MDWD)?
- On a trailing-twelve-month basis, MDWD trades at a P/E ratio of -7. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Mediwound?
- MDWD has a market capitalization of about $168M. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.